NCT05082181 Telephone-Based Support Programs for People With Epilepsy
| NCT ID | NCT05082181 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2021-11-09 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2021-11-09 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a two-arm randomized controlled trial to compare telephone-based depression self-management (UPLIFT) to telephone-based support groups (BOOST). A sample of 120 English- and Spanish-speaking people with epilepsy (PWE) with elevated depressive symptoms will be enrolled. Both interventions are 8-week programs delivered in one-hour weekly sessions to groups of about 6 participants. Changes in depressive symptoms, quality of life and seizures will be assessed over 12 months. The trial will also examine mediators and moderators of treatment effects.
Eligibility Criteria
Inclusion Criteria: * adult (≥18 years of age); * diagnosed with epilepsy for at least one year; * fluent in English or Spanish; * elevated depressive symptoms (PHQ-9 score ≥10); * willing to participate in audiotaped group telephone sessions Exclusion Criteria: * severe depressive symptoms (PHQ-9 ≥20); * active suicidal ideation (PHQ-9 item #9 ≥1 or otherwise reported during screening); * active psychotic disorder (psychiatric diagnosis or antipsychotic medications in the EHR); * significant cognitive impairment (indicated in EHR or evident during screening)
Contact & Investigator
Daniel Friedman, MD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT05082181 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05082181 currently recruiting?
Yes, NCT05082181 is actively recruiting participants. Contact the research team at Tanya.Spruill@nyulangone.org for enrollment information.
Where is the NCT05082181 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05082181 clinical trial?
NCT05082181 is sponsored by NYU Langone Health. The principal investigator is Daniel Friedman, MD at NYU Langone Health. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.